Boston Scientific Spinal Cord Stimulator Lawsuits Consolidated Into a New Federal MDL

A spinal cord stimulator is supposed to be a last line of relief. People reach for one after back surgery has failed, after years of nerve pain, after the prescriptions stopped working. The device — a battery-powered generator wired to thin leads placed near the spinal cord — sends mild electrical pulses meant to drown out pain signals before the brain registers them. For some patients it works. For others, according to a growing body of lawsuits, the implant became a second source of injury.

On June 5, 2026, the U.S. Judicial Panel on Multidistrict Litigation (JPML) took a procedural step that signals this litigation has reached a critical mass: it ordered 23 lawsuits against Boston Scientific — scattered across nine different federal districts — to be consolidated before a single federal judge. The new case is captioned In re: Boston Scientific Corporation Spinal Cord Stimulator Products Liability Litigation, MDL No. 3181, assigned to U.S. District Judge Josephine L. Staton in the Central District of California.

What an MDL Is — and What It Is Not

This is the point most headlines get wrong, so it is worth being precise. An MDL is not a class action. In a class action, one group of people is treated as a single unit and shares one outcome. In a multidistrict litigation, every plaintiff keeps their own individual case, with their own facts, their own injuries, and their own potential outcome. The cases are simply pulled together in front of one judge so that the shared pretrial work — gathering company documents, taking expert testimony, deciding common legal questions — happens once instead of 23 separate times in 23 separate courthouses.

For an injured patient, the practical takeaway is this: the formation of MDL 3181 makes the litigation more organized and more efficient, but it does not merge your situation into a faceless group. If you file, your medical records, your specific device, and your specific surgeries still matter individually.

What the Lawsuits Actually Allege

According to the JPML’s own description of the consolidated cases, the Boston Scientific lawsuits share a set of core allegations. The Panel noted that plaintiffs claim the company:

• Relied on studies of competitors’ devices instead of conducting its own independent clinical testing of the stimulators at issue;
• Used the FDA’s “PMA supplement” pathway to push out substantially modified versions of its stimulators without the additional testing that a brand-new device would ordinarily require; and
• Failed to adequately disclose the risks associated with the devices to patients and physicians.

That second point is the one a medical-legal eye lingers on. The premarket approval (PMA) “supplement” process is a legitimate, FDA-sanctioned way for a manufacturer to update an already-approved device. But the lawsuits allege it was used to roll out meaningfully changed hardware and software while leaning on the testing done for earlier models — so that newer stimulators reached patients without fresh, device-specific clinical data behind them. Whether that allegation holds up is exactly what the discovery phase of an MDL is built to test.

The Injuries Patients Are Reporting

The injuries described in the filings are not minor inconveniences. They include:

• Fracture of the lead wires that run to the spinal cord
• Migration — the leads or the generator shifting out of position after implant
• Unintended electrical shocks or overstimulation
• Worsening or returning chronic pain the device was meant to relieve
• Severe nerve pain, spinal cord compression, and permanent nerve damage
• Infection at the implant site
• The need for additional surgery to revise or remove the device
• In the most serious cases, spinal cord injury and wrongful death

A recurring theme is the revision surgery — the operation to take out or reposition a device that was supposed to end the patient’s suffering. For someone who only agreed to an implant because conservative care had already failed, a second or third surgery is not a footnote. It is the heart of the harm.

Why Boston Scientific — and Why Not Abbott (Yet)

Boston Scientific opposed the creation of this MDL. The JPML formed it anyway, finding that the cases shared enough common questions to justify centralization. Notably, the Panel declined — for now — to centralize lawsuits involving Abbott spinal cord stimulators, leaving those cases to proceed individually, though it signaled that Abbott claims could be gathered into their own MDL later if that litigation grows.

One point deserves emphasis: the formation of an MDL is a procedural step, not a finding of fault. Boston Scientific disputes the claims, and none of the allegations described here have been proven in court. Centralizing the cases simply means a single judge will oversee the evidence-gathering that will eventually test whether those allegations hold up.

For patients, this distinction is not academic. The manufacturer and model of your specific device determine which legal track your situation falls on. A Boston Scientific device points toward MDL 3181; an Abbott device currently does not. This is one reason the single most useful thing you can do is locate your device’s manufacturer card or implant records — the small wallet card or the operative report that names the exact system you received.

What to Do If You Have a Stimulator

• Talk to your treating physician first about any device problems — pain, shocks, infection, or a malfunction. Your health comes before any legal step.
• Do not remove or stop using the device on your own. Revision is a surgical decision only your doctor can make.
• Find your device information — the manufacturer wallet card, the implant sticker, or the operative report that names the brand and model.
• Keep your records — surgical reports, imaging, follow-up notes, and anything documenting a revision or removal.
• Confirm your deadline. The statute of limitations varies by state and by when you knew the device caused harm. Waiting can permanently end the right to file.

Common Questions